

Please type a plus sign (+) in this box +

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	-00/865,812-10/613,105
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	05/25/01
		First Named Inventor	Rastelli
		Group Art Unit	1632
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	21402-018 (Cura-318)

U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate	
JM	A1	5,871,697	02/16/99	Rothberg et al.			10/24/95	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1				

OTHER PRIOR ART - NONPATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
JM	C1	Capecchi, M. (1989). "Altering the genome by homologous recombination." <i>Science</i> 244: 1288-1292.			
JM	C2	Heinzel, R. et al. (1986). "Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus." <i>Eur. J. Biochem.</i> 160(1): 61-67. GenBank Accession Number: X04470			
JM	C3	Shimkets, R. et al. (1999). "Gene expression analysis by transcript profiling coupled to a gene database query." <i>Nat Biotechnol</i> 17(8): 798-803.			

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	2/15/06
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1601217v1

Please type a plus sign (+) in this box

Modified Form 1449/PTO		Application Number	09/665,812 — 16/613,812
		Filing Date	05/25/01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Rastelli
(use as many sheets as necessary)		Group Art Unit	1635
		Examiner Name	Lacourciere, Karen A.
		Attorney Docket Number	21402-018 (Cura-318)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
(P)	A2	5,633,227	05/27/1997	Muller, et al.			09/12/1994
J	A3	4,980,281	12/25/1990	Housley			02/10/1988

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B						

OTHER PRIOR ART - NONPATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
(K)	C4	Abe, et al. (1997). "Bacteria pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung." <i>American Journal of Respiratory and Association</i> . <u>156</u> : 1235-1240.					
	C5	Bingle, et al. (1996). "Secretory leukoprotease inhibitor: partnering alpha1-proteinsase inhibitor to combat pulmonary inflammation." <i>Thorax</i> . <u>51</u> (12): 1273-1274.					
	C6	EMBASE Online Accesion No.: P03973. 10/23/1986.					
	C7	EMBASE Online Accesion No.: X04470. 03/09/1987.					
	C8	Fath, et al. (1998). "Interaction of secretory leukocyte protease inhibitor with heparin inhibits protease involved in asthma." <i>Journal of Biological Chemistry</i> . <u>273</u> (22): 13563-13569.					
	C9	Gipson, et al. (1999). "Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury." <i>Journal of Immunology</i> . <u>162</u> (6): 3653-3662.					
	C10	Kida, et al. (1992). "Serum secretory leukoprotease inhibitor levels to diagnose pneumonia in the elderly." <i>The American Review of Respiratory Disease</i> . <u>146</u> (6): 1426-1429.					
	C11	Thompson, et al. (1986). "Isolation properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase." <i>Proceedings of The National Academy of Sciences of USA</i> . <u>83</u> : 6692-6696.					
	C12	Van Wetering, et al. (2000). "Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins." <i>American Journal of Physiology</i> . <u>278</u> (1): L51-L58.					
	C13	Vogelmeier, et al. (1996). "Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity." <i>Chest</i> . <u>110</u> (6): 261S-266S.					
	C14	Wright, et al. (1999). "Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma." <i>The Journal of Pharmacology and Experimental Therapeutics</i> . <u>289</u> (2): 1007-1014.					
	C15	Partial International Search Report for PCT/US01/17211. Mailed February 26, 2003.					

Express Mail N :: EV109727221US
Dat of Dep sit: April 30, 2003

Page 2 of 2

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	2/15/06
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1786036v1